索拉非尼治疗晚期肝细胞癌
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
NGC banner
Guideline Summary NGC-7914
Guideline Title
Sorafenib for the treatment of advanced hepatocellular carcinoma.
Bibliographic Source(s)
National Institute for Health and Clinical Excellence (NICE). Sorafenib for the treatment of advanced hepatocellular carcinoma. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 May. 34 p. (Technology appraisal guidance; no. 189).
Guideline Status
This is the current release of the guideline.
Scope
Disease/Condition(s)
Advanced hepatocellular carcinoma (HCC)
Guideline Category
Assessment of Therapeutic Effectiveness
Treatment
Clinical Specialty
Family Practice
Gastroenterology
Internal Medicine
Oncology
Intended Users
Advanced Practice Nurses
Nurses
Physician Assistants
Physicians
Guideline Objective(s)
To evaluate the clinical effectiveness and cost-effectiveness of sorafenib for the treatment of advanced hepatocellular carcinoma (HCC)
Target Population
Patients with advanced hepatocellular carcinoma for whom surgical or locoregional therapies have failed or are not suitable
Interventions and Practices Considered
Sorafenib was considered but not recommended
Major Outcomes Considered
l Clinical effectiveness
l Overall survival
l Progression free survival
l Time to symptomatic progression
l Tumor response
l Health related quality of life
l Adverse effects of treatment
l Cost-effectiveness
Methodology
Methods Used to Collect/Select the Evidence
NICE has developed tools to help organisations put this guidance into practice (listed below). These are available on
Electronic copies: Available in Portable Document Format (PDF) format from the
Institute for Health and Clinical Excellence (NICE); 2010 May. 2 p. (Technology appraisal 189). Available in Portable
.
Institute for Health and Clinical Excellence (NICE); 2010 May. 1 p. (Technology appraisal 189). Available in PDF
London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 May. 6 p. (Technology appraisal 189).
.
Sorafenib for advanced hepatocellular carcinoma. Evidence review group report. West Midlands Health Technology
NHS services. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 May. 4 p. Available in
National Institute for Health and Clinical Excellence (NICE) Web site. Also
.
the development or adaptation of NICE guidance for use in any other country. The full versions of all NICE guidance can
.